Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 8 months ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 1 year ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more
Author(s): Felicita Andreotti , Diana Gorog , Marco Valgimigli , et al Start date: Dec 14, 2023
This live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), will demonstrate how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Join key opinion leadersProf Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese (University of Sassari,… View more
Author(s): , Added: 8 months ago
In this video series, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between… View more
Author(s): Amish Raval Added: 1 month ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more
Author(s): Christophe Leclercq Added: 1 month ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire… View more